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Introduction
Body magnesium is distributed in three major
compartments: extracellular fluid (1.3%), intracellular
fluid (13%) and bone (67%). Thus, Mg is mainly locat-
ed in areas that are poorly accessible to study: the
intracellular and body compartments. Unfortunately,
most of the available data on electrolyte metabolism is
derived from measurements of the blood concentra-
tion of Mg. Today we can diagnose Mg disbalance
measuring this electrolyte in extracellular fluid (serum),
intracellular fluid (erythrocyte, lymphocyte) and urine
(1, 2). Lymphocyte and skeletal muscle Mg have been
used for research purposes, but usually are not avail-
able in clinical practice because of the complexity of
their determination. Determination of erythrocyte Mg
value is the most precise, since Mg is primarily an
intracellular cation, but many laboratories are deficient
in this method. It is sometimes extremely difficult to
precisely judge body Mg content in clinical reports and
experimental studies that measure only the serum lev-
els. Hypomagnesemia can develop without concomi-
tant magnesium losses and cellular magnesium
depletion can occur in the presence of normomagne-
semia (3). However, with all its limitations, a serum Mg
concentration remains the prime clinical diagnostic
tool. Simultaneous investigation of Mg in serum and in
24-hour urine is a precious method for observation of
Mg disbalance in clinical practice. Serum Mg concen-
tration is not routinely measured when physicians ini-
tiate a request for determination of serum electrolytes.
Various studies indicated that patients with acute and
chronic pulmonary disease may have Mg disbalance
(1’ 2, 4 ’ 5).
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Summary: In this study we determined magnesium concentration in serum and in 24-hour urine, at the
start (To) and at the end of treatment (T1), in 56 patients with acute pulmonary disease (B1) and in 58 patients
with chronic obstructive pulmonary disease ’ COPD (B2). In group B1 there was disbalance of Mg in serum in
14’25% patients at the start of treatment (To) which decreased significantly at the end of treatment (T1) and per-
sisted in 4’7.1% patients (p < 0.05). In group B2 distribution of normal, decreased and increased values of Mg
in serum was similar in patients in period To and T1 (p > 0.05). In group B1, 9 (16.1%) patients had hypomag-
nesemia at the start of treatment (To), which was accompanied by increased concentration of Mg in 24-hour urine
of only 4 (7.2%) patients. There is a possibility that there was extrarenal elimination of Mg in patients with acute
pulmonary disease or there was some kind of transcellular distribution. In group B2 in period To, there was pro-
portional ratio between hypomagnesemia (12’20.7% patients) and increased concentration of Mg in 24-hour
urine (20 ’34.5% patients). This could be because of renal loss. Simultaneous determination and follow up of
magnesium in serum and in 24-hour urine can give us reliable information about homeostasis of this electrolyte
in acute and chronic pulmonary diseases.
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Materials and Methods
Materials
We investigated 114 patients, 56 with acute pul-
monary disease (B1) (with the subgroups B1-1: 18
patients with pneumonia, B1-2: 22 patients with pul-
monary thromboembolism, B1-3: 16 patients with
acute asthma attack) and 58 patients with acute exac-
erbation of chronic obstructive pulmonary disease -
COPD (B2). The following ratio between males and
females were in group B1 = 34’60.7% : 22’39.3%
(B1-1 = 14’77.8% : 4’22.2%; B1-2 = 13’59.1% : 9
’40.9%; B1-3 = 7’43.8% : 9’56.2%) and in group
B2 = 33’56.9% : 25’43.1%. In group B1 patients
were of mean age 46.8 ± 15.3 years (B1-1: 47.1 ±
15.9; B1-2: 49.7 ± 13.4; B1-3: 42.2 ± 16.9) and 61.7
± 7.7 years in group B2. 
Methods
We measured Mg concentration in serum and 24-
hour urine in patients by colorimetric Calmagite method
using biochemical analyzer IL Monarch 2000 (Instru-
mentation Laboratory, Milano, Italy). Reference values
for Mg in serum were 0.70’1.15 mmol/L and in 24-
hour urine were 3’5 mmol/day (6).
We determined Mg concentration in serum and
24-hour urine in patients at the start (To) and at the
end of  hospital treatment (T1). All patients were first
admitted in Pulmonary Intensive Care Unit and after
stabilization of disease they continued treatment in the
clinical department.
In this study there were not patients with associ-
ate diseases which can be a potential risk factor for
electrolyte disbalance like: gastrointestinal diseases
(Malabsorption syndromes, ulcus disease, malnutri-
tion for hard dietary, severe diarrhoea, pancreatitis,
etc.), pregnancy and prolonged lactation, hormonal
diseases (Diabetes mellitus, hyperthyroidism, hypothy-
roidism, diseases glandulae suprarenalis, etc), renal
failure, malignant disease, and alcoholism.
The results are presented as mean values (⎯x)
with dispersion measures: standard deviation (SD),
coefficient of variation (CV) and standard error (SE),
minimal and maximal values (Min-Max) and median
values. A statistical analysis was performed using Stu-
dent's t-test, Mann-Whitney test and Pearson's c2 test.
Differences were considered as statistically significant
at p < 0.05.
Results
In the group of patients with acute pulmonary
disease (B1) 22 patients (39.3%) had high temperature
over 38 ºC  and in the group with acute exacerbation
of chronic obstructive pulmonary disease ’ COPD
(B2) were  27 patients ( 18.7%) (c2 = 0.614; DF = 1,
p > 0.05). On hospital admission 45 patients (80.3%)
with acute pulmonary diseases (B1) had acute distur-
bance of respiratory gasses in arterial blood. Partial
pressure of oxygen in arterial blood (PaO2) was lower
than 8 kPa in 7 patients (38.9%) with pneumonia (B1-
1), in 5 patients (22.7%) with pulmonary thromboem-
bolism (B1-2) and in 9 patients (56.3%) with acute
asthma attack (B1-3). In group B2 on admission all 58
patients (100%) had acute exacerbation of chronic res-
piratory failure. Mean value of PaO2 in group B1 was
8.85 ± 1.65 kPa and in B2 4.86 ± 0.92 kPa (t =
15.964; DF=1, p<0.001). Decompensation status of
cor pulmonale chronicum persisted in 39 patients
(67.2%) with acute exacerbation of COPD (B2).
In patients with acute pulmonary disease (B1) the
most lowest value of Mg in serum on admission (To)
was 0.48 mmol/L and the highest was 1.27 mmol/L.
The mean concentration of this electrolyte was in refe-
rence range (0.88 ± 0.16 mmol/L). In patients with
acute exacerbation of COPD (B2) mean concentration
of  Mg in serum in period To (0.86 ± 0.16 mmol/L) was
normal like in group B1 (B1:B2 t = 0.649; DF=112,
p>0.05). After administered therapy at the end of hos-
pitalization (T1) in both groups mean concentration of
Mg in serum was normal but lower in group B2 (0.87 ±
0.14 mmol/L) than in group B1 (0.94 ± 0.17 mmol/L)
(t = 2.094; DF = 112, p < 0.05). By comparing indi-
vidual analyses within group B1 and group B2 there
were not statistically significant differences in mean
concentrations of Mg in serum before (To) or after
treatment (T1) (p > 0.05) (Table I).
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t = 2.094; DF = 112; p < 0.05*
B1 ’ t = 1.788; p > 0.05*


































































































Table I   Magnesium concentration in serum (mmol/L) 
at the start (To) and at the end of treatment (T1) 
in groups of patients
In comparison with reference values (normal,
decreased and increased), patients with acute pul-
monary disease (B1) had important differences in dis-
tribution of Mg serum concentration at the start (To)
(normal = 75.0%; decreased = 16.1%; increased =
8.9%) and at the end of treatment (T1) (normal =
92.9%; decreased = 5.3%; increased = 1.8%) (p <
0.05). There is an interesting occurrence disbalance in
this electrolyte in serum in patients with acute asthma
attack (To) (43.8% patients had disturbance). Among
them, 25% of patients had decreased and 18.8%
increased concentration of magnesium. After therapy
(T1) this disbalance was completely corrected and all
patients had normal concentration of Mg (p < 0.05).
Patients with acute exacerbation of COPD (B2) had
similar values, normal, decreased and increased con-
centrations before and after therapy (p>0.05).
Comparing Mg distribution in serum between groups
B1 and B2 we registered not significant differences in
period To (c2 = 0.032; DF = 1, p > 0.05) but signifi-
cant in period T1 (c2 = 4.33; DF = 1, p < 0.05) (Ta-
ble II ).
Mean concentration of Mg in 24-hour urine in
patients from group B1 and group B2 at period To
and T1 was shown in Table III.
In Table IV we can see distribution normal, de-
creased and increased concentrations of Mg in 24-
hour urine in patients from group B1 and group of B2.
There are interesting findings in group B2 where
patients had high percentage of increased concentra-
tion of Mg in 24-hour urine both at the start (To) and
at the end of treatment (T1).
Discussion
Disbalance of Mg serum concentration is not a
rare appearance in patients with pulmonary diseases
(1’4). Results from literature described frequency of
hypomagnesemia in 10’60% among hospital treated
patients, especially in patients who were medically tre-
ated in Intensive Care Units. Greater mortality was
seen in patients with hypomagnesemia, comparing
with patients who had normal concentrations, espe-
cially when they were treated in Intensive Care Unit (7).
Results of this study showed that mean concen-
tration of Mg in serum at the start (To) and at the end
of medical care (T1) were in referential value in group
B1 and group B2.
Analyzing various patients in group B1 we found
that patients with acute asthma attack (B1-3) had the
lowest Mg serum concentration in period To (0.48
mmol/L) while the highest concentration (1.27 mmol/L)
was found in patients with pulmonary thromboembo-
lism (B1-2). 
Patients with acute pulmonary disease (B1) had
important differences in distribution of Mg serum con-







B1:B2 c2 = 0.032;   DF=1;   p > 0.05** c2 = 4.33;   DF=1;   p < 0.05**
























































































Table II.   Distribution of magnesium concentration in serum at the start (To) and at the end of treatment (T1)
To
T1
Z = 2.553; p < 0.015*
Z = 5.492; p < 0.001*
B1 ’ Z = 0.958; p > 0.05*


































































































Table III   Magnesium concentration in 24-hour urine
(mmol/day) at the start (To) and the end of treatment (T1)
in groups of patients
centrations between the start (To) and the end of treat-
ment (T1) (p < 0.05). They had hypomagnesemia
(16.1% patients) more frequently  than hypermagnese-
mia (8.9% patients) at the start of hospitalisation. To-
tal Mg serum disbalance was present in 25% patients
of group B1 in period To, which is similar to results of
other authors. They therefore recommended that se-
rum Mg be included routinely when serum electrolyte
measurements are required in the care of patients (8,
9). Hypomagnesemia in patients with acute pulmo-
nary disease may be a result of severe infections, inap-
propriate secretion of antidiuretic hormone (ADH),
antibiotic administration (aminoglycoside) (3), etc.
Hypomagnesemia was more frequently found in
patients with acute asthma attack (B1-3: 25.0% pa-
tients) than in patients with pneumonia (B1-1: 11.1%
patients) and patients with pulmonary thromboem-
bolism (B1-2: 13.6% patients).
There was an interesting appearance that 43.8%
patients with acute asthma attack (B1-3) had Mg serum
disturbance in a period of bronchoobstruction which
was the reason for hospital care. After medical treat-
ment all disbalances were corrected (p < 0.05). Pa-
tients had hypomagnesemia (25.0%) more commonly
than hypermagnesemia (18.8%). Some authors did not
discover Mg disbalance in patients with asthma attack
(10), but others confirmed significant disturbance of
this electrolyte usually as hypomagnesaemia (11). Mg
depletion may affect muscle function (3), so hypomag-
nesemia can be one of the reasons for appearance of
bronchoobstruction in patients with asthma attack.
Various medicaments can produce Mg and other elec-
trolyte disturbance. Frequently administered nebulized
albuterol (beta-adrenergic agonist) during the emer-
gency treatment of acute bronchospasam in patients
with asthma decreases serum potassium, magnesium
and phosphate (12). Intravenous theophylline adminis-
tered in patients with asthmatic attacks can produce
hypophosphatemia, hypomagnesaemia and hypocal-
caemia (2). Hashimoto (11) confirmed decreased Mg in
40% patients with asthma and he compared it with
severity of bronchoobstruction. The majority of  authors
advised administration of magnesium-sulfate to
improve pulmonary function in patients with acute asth-
ma attack (13’15). Continuous medical treatment with
oral magnesium 300 mg/day during two months
reduces asthma morbidity in children and adolescents,
and helps to improve their lung function (14). Besides
recommended treatment by Global Strategy for Asth-
ma Management and Prevention (16), administration of
2 g IV magnesium sulfate improves pulmonary function
when used as an adjunct to standard therapy in patients
with very severe acute asthma (15).
We can expect different electrolyte disbalance,
also Mg disturbance in patients with acute pulmonary
disease (17).
In 25.9% patients at the start acute exacerbation
of COPD (B2) Mg serum disbalance persisted more
frequent as hypomagnesaemia (20.7% patients) than
hypermagnesiemia (5.2% patients). Comparing distri-
bution of Mg in serum between patients in group B1
and B2 we confirmed not significant differences et the
start (To) (c2 = 0.032; DF = 1; p>0.05) but signifi-
cant differences at the end of treatment (T1) (c2 =
4.33; DF=1; p < 0.05).
Various electrolyte disbalance is not an uncom-
mon appearance in patients with acute exacerbation
of COPD (18). In this study there were a greater num-
ber of patients with decreased Mg in serum (20.7%)
than in results of Hogg et al (11.8%) (19). There is a
study which shows that exacerbation of COPD signifi-
cantly affected magnesium levels in erythrocytes, while
in plasma levels it remained unchangeable (20).
Administration of systemic corticosteroids and diure-
tics can be a possible reason for hypomagnesemia in
patients with acute exacerbation of COPD (4).
Comparing distribution of Mg concentration in
serum and in 24-hour urine in patients of group B1 at
the start of treatment (To), it was not confirmed that
hypomagnesemia (16.1% patients) was in proportion-
al ratio with increased urine concentration (7.2% pa-
tients). Therefore was suspected that patients with
acute pulmonary disease had extrarenal electrolyte







B1:B2            c2 = 0.84; DF = 1; p > 0.05** c2 = 0.03; DF = 1; p > 0.05***
* In comparison with reference values























































































Table IV   Distribution of magnesium concentration in 24-hour urine at the start (To) and at the end of treatment (T1)
elimination or transcellular arrangement from extra-
cellular to intracellular space. In patients of group B2
also at the start of hospital care (To) there was a bet-
ter proportional ratio between decreased Mg in serum
(20.7% patients) and increased urine level (34.5%
patients). We explained these results by renal elec-
trolyte elimination, mostly because of using loop diu-
retics in patients who had cor pulmonale chronicum in
decompensated state.
Results of this study showed that we can expect
magnesium disbalance in patients with acute and
chronic pulmonary diseases. Measuring Mg in serum
and in 24-hour urine is a very useful method for follow-
up of electrolyte disturbance. We recommend that
should be determined and followed up Mg concentra-
tion in pulmonary diseases especially in patients with
acute asthma attack.
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Kratak sadr`aj: U ovom radu odre|ivana je koncentracija magnezijuma u serumu i u 24-urinu, na po~etku
(To) i na kraju hospitalnog le~enja (T1) kod 56 bolesnika sa akutnim plu}nim bolestima (B1) i kod 58 sa
hroni~nim plu}nim bolestima (B2). U grupi B1 postojao je disbalans Mg u serumu kod 14’25% bolesnika na
po~etku le~enja (To) koji se zna~ajno smanjio na kraju le~enja (T1) i postojao je kod 4’7,1% bolesnika (p < 0,05).
U grupi B2 distribucija normalnih, snizenih i povi{enih vrednosti Mg u serumu bila je sli~na u periodu To i T1 (p>
0,05). Hipomagnezemiju u grupi B1 imalo je 9 (16,1%) bolesnika na po~etku le~enja (To) {to je bilo pra}eno
pove}anom koncentracijom Mg u 24-~asovnom urinu samo kod 4 (7,2%) bolesnika. Ovo je bilo mogu}e zbog
ekstrarenalnog gubitka elektrolita ili je do{lo do transcelularne preraspodele. U grupi B2 u periodu To postojao je
proporcionalni odnos hipomagnezemije (12,0’20,7% bolesnika) sa pove}anom koncentracijom Mg u 24-~asov-
nom urinu (20,0’34,5% bolesnika). Ovo je bilo mogu}e zbog renalne eliminacije elektrolita. Istovremeno odre|i-
vanje i pra}enje magnezijuma u serumu i 24-~asovnom urinu daje pouzdane informacije o homeostazi ovog elek-
trolita kod akutnih i hroni~nih plu}nih bolesti.
Klju~ne re~i: magnezijum, serum, urin, plu}ne bolesti
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